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Volume 52, Number 5 Abstracts 1421or who died at 6 months of their initial VTE. Included patients were
monitored with clinical examination at 3, 6, and 12 months and annually for
at least 5 years. Patients with proximal DVT were anticoagulated for at least
6 months. Those with calf DVT were anticoagulated for 3 months or were
monitored with ultrasound imaging for 3 weeks. If the calf DVT progressed,
the patients were anticoagulated; if it did not, they remained on compression
stockings and aspirin or nonsteroidal anti-inflammatory drugs. Patients
underwent duplex ultrasound imaging at least twice in the first year and at
any time when there were symptoms suggestive of recurrent VTE. Duplex
examinations were also performed at 5 years and anytime later for those with
longer follow-up. DVT recurrence was defined as thrombus in a new
location from the original DVT when the extent of thrombus at the follow
up examination was 9 cm, when a previously recanalized segment subse-
quently exhibited non-compressibility, and when thrombus thickness was
2 mm for distal veins and 4 mm for proximal veins. This prospective
observational study enrolled 153 consecutive patients. Location and extent
of the initial DVT, PE, recurrent VTE, causes of mortality, signs and
symptoms of post-thrombotic syndrome, and risk factors of VTE were
recorded.
Recurrent VTE occurred in 26.1% by 5 years. Patients who had both
proximal and distal DVT had similar recurrence rates compared with those
patients with proximal DVT alone (17 of 48 [35%] vs 12 of 49 [24%], P 
.27). There appeared to be a trend toward higher recurrence rates in patients
with proximal and distal DVT than those with calf DVT alone (P  .08). A
higher recurrence was associated with unprovoked DVT (relative risk [RR],
2.9; 95% confidence interval [CI], 1.5-5.7; P .01) and age65 years (RR,
1.5; 95% CI, 1-23; P .025;). There was no demonstrated increased risk of
recurrence with thrombophilia (P  .21). There was low recurrence in
patients with DVT associated with surgery or trauma (P  .001). Increased
severity of post thrombotic syndrome was associated with ipsilateral recur-
rence (RR, 1.6; 95%CI, 1.4-2.2; P .001). PE was diagnosed 47 times, and
12 of 47 (25%) incidences of PE were fatal.
Comment: The study has severe limitations due to sample size. The
number of patients is too small to provide meaningful subgroup analysis.
The number of patients ultimately dying of PE is a bit shocking, but perhaps
what is most interesting in this field is the increasing frequency of reports
contradicting the widely held belief that thrombophilia is a risk factor for
recurrence of VTE. Clearly, as in this study, many patients with thrombo-
philia have other risk factors for VTE that make it difficult to independently
assess the impact of thrombophilia on VTE recurrence. Despite the results
here, until larger and better studies have examined the impact of thrombo-
philia on VTE recurrence, it may be best to still consider thrombophilia as a
risk factor for recurrent VTE.
Relation Between Preoperative and Intraoperative New Wall Motion
Abnormalities in Vascular Surgery Patients: A Transesophageal Echo-
cardiographic Study
Galal W, Hoeks SE, Flu WJ, et al. Anesthesiology 2010;112:557-66.
Conclusion: There is a poor correlation between new wall motion
abnormalities (NWMAs) observed intraoperatively using transesophageal
echocardiography (TEE) and preoperative stress-induced NWMAs assessed
by dobutamine echocardiography.
Summary: Intraoperative TEE can detect regional wall motion abnor-
malities in patients undergoing major noncardiac surgery. However, it is
unclear whether NWMAs detected intraoperatively with TEE actually cor-
relate with abnormalities detected preoperatively with noninvasive stress
testing. The authors sought to determine whether wall motion abnormali-
ties identified with dobutamine echocardiography correlate with those ob-
served intraoperatively with TEE.
Fifty-four patients undergoing major vascular surgery underwent pre-
operative dobutamine echocardiography and intraoperative TEE. A seven-
wall model scoring system was used to determine the locations of left
ventricular rest wall motion abnormalities and NWMAs discovered with
preoperative stress testing or with intraoperative TEE. Postoperative cardiac
troponin levels, myocardial infarction, and cardiac death were noted during
a 30-day follow-up. Wall motion abnormalities at rest were detected by
dobutamine echocardiography in 17 patients (31%). TEE noted NWMAs in
16 patients (30%). NWMAs were induced with dobutamine in 17 patients
(31%). NWMAs were observed by TEE in 23 patients (43%,   0.65).
There was excellent agreement between preoperative and intraoperative rest
wall motion abnormalities (  0.92); however, agreement for preoperative
and intraoperative new wall motion abnormalities in different locations was
poor (  0.26-0.44). A composite cardiac end point of increased troponin
levels, myocardial infarction, or cardiac death occurred in 15 patients (26%),
of whom 10 patients (67%) experienced both preoperative and intraopera-
tive NWMAs. Only intraoperative NWMAs were observed in four (27%). In
the six patients who experienced a postoperative myocardial infarction, the
location of the electrocardiographic changes correlated with intraoperatively
observed NWMAs by TEE.
Comment: In this series there were no cardiac deaths or postoperative
myocardial infarctions in patients without intraoperative NWMAs. Because
reproducibility of wall motion abnormalities at different perioperative timeswas not achievable in this study, the suggestion is that optimized medical
therapy remains superior over invasive interventions focused on preoperative
detection of culprit lesions. The data indicate patients with intraoperative
NWMAs detected by TEE are perhaps the highest risk group for periopera-
tively significant cardiac events. Such patients demand perhaps the most
assiduous perioperative management of cardiac parameters.
Risk Factors and Outcome of New-Onset Cardiac Arrhythmias in
Vascular Surgery Patients
Winkle TA, Schouten O, Hoeks SE, et al. Am Heart J 2010;159:1108-15.
Conclusion: Perioperative arrhythmias are common after vascular
surgeries. Elderly patients and those with reduced left ventricular function
are particularly prone to postoperative arrhythmias.
Summary:Cardiac arrhythmia occurring postoperatively can be seen in
up to 20% of patients undergoing noncardiac surgery (Brathwaite D, et al,
Chest 1998;114:462-8 and Walsh SR et al, Ann R Coll Surg Engl 2007;89:
91-5). The risk of cardiovascular events is especially elevated in noncardiac
vascular surgical patients (Schouten O et al, Eur Heart J 2008;29:283-4).
Many events are asymptomatic and often transient and unpredictable, sug-
gesting the true prevalence may be underestimated. The current study
focused on vascular surgical patients and was designed to determine the true
prevalence of cardiac arrhythmias in this population, identify operative risk
factors leading to new-onset cardiac arrhythmias, and assess the impact of
these new arrhythmias on postoperative outcome.
The study included 515 vascular surgical patients without a history of
arrhythmia. Assessed were left ventricular function (LVF), determined by
N-terminal pro-B-type natriuretic peptide levels and echocardiography,
inflammatory status, and cardiac risk factors. New onset arrhythmias and
ischemia were identified with 72-hour continuous electrocardiographic
recordings. Patients were evaluated for atrial fibrillation, sustained ventric-
ular tachycardia, supraventricular tachycardia, and ventricular fibrillation.
There was a new onset of arrhythmia in 55 patients (11%), including atrial
fibrillation in 4%, ventricular tachycardia in 7%, supraventricular tachycardia
in 1%, and ventricular fibrillation in 0.2%. Arrhythmia was preceded by
ischemia in 10 of 55 patients. Reduced LVF and increased age were risk
factors for development of arrhythmia. Multivariant analysis indicated that
perioperative arrhythmias were associated with long-term cardiovascular
events independent of perioperative ischemia (hazard ratio, 2.2; 95% confi-
dence interval, 1.3-3.8; P  .004).
Comment:More than 30 years ago, Goldman published a prospective
series of patients undergoing major noncardiac surgery, and only 4% devel-
oped postoperative supraventricular arrhythmias (Goldman L, Chest 1978;
73:450-4). One conclusion was that postoperative supraventricular arrhyth-
mias were often transient, and the most important thing was to correct the
cause of the arrhythmia. The number of each type of arrhythmia occurring in
this study did not permit meaningful subset analysis. The association of
arrhythmias with older age and preoperatively decreased LVF is not all that
surprising. Currently, many vascular surgical patients are routinely subjected
to telemetry monitoring. Given the number of arrhythmias identified in this
study, the current data may question the use of such a blanket policy for
patients without known preoperative left ventricular dysfunction.
The Phosphodiesterase Inhibitor Cilostazol Induces Regression of
Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus
Principal Results of the Diabetic Atherosclerosis Prevention by Cilosta-
zol (DAPC) Study: A Randomized Trial
Katakami N, Kim Y-S, Kawamori R, et al. Circulation 2010;121:2584-91.
Conclusion: Cilostazol provides greater inhibition of progression of
carotid intima-medial thickness than aspirin in patients with type 2 diabetes
mellitus.
Summary: It appears patients with diabetes without previous myocar-
dial infarction have as high a risk of myocardial infarction as patients without
diabetes and previous myocardial infarction (Haffner SM, et al, N Engl
J Med 1998;339:229-34). On the basis of this, some have advocated that
primary prevention in patients with diabetes may be indicated. Guidelines
suggest that individuals with risk factors for coronary heart disease, such as
diabetes mellitus, should take aspirin for primary and secondary prevention,
although the ability of aspirin to effectively serve as a primary preventive
agent is controversial (American Diabetes Association, Diabetes Care 2007;
30:s4-41). There has been some suggestion that cilostazol may be effective
in preventing cardiovascular events in patients with type 2 diabetes mellitus
(Shinohara Y, et al, Cerebrovasc Dis 2008;26:63-70). This study therefore
compared the ability of two antiplatelet agents, aspirin and cilostazol, to
prevent progression of carotid intima-media thickness. This was a prospec-
tive, randomized, open, blinded end point study conducted in four East
Asian countries. The study enrolled 329 type 2 diabetic patients suspected of
peripheral arterial disease (PAD). Patients were eligible if they were aged 40
to 85 years at the time of enrollment and were suspected of PAD on the basis
of an ankle-brachial index 1.0, poor pulses, or clinical symptoms of PAD.
Patients were allocated to receive aspirin (81-100 mg/d) or cilostazol
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media thickness of the common carotid artery after 2 years. Regression in
maximum left, maximum right, mean left, and mean right common carotid
artery intima-media thickness was greater with cilostazol than with aspirin
(–0.088  0.260 vs 0.059  0.275 mm, P  .001; –0.042  0.074 vs
0.045  0.216 mm, P  .03; –0.043  0.182 vs 0.028  0.202 mm, P 
.004; and –0.024  0.182 vs 0.048  0.169 mm, P  .001). Results
persisted when data were adjusted for possible confounding variables such as
hemoglobin A1C and lipid levels.
Comment: Cilostazol is a phosphodiesterase-3 inhibitor and has anti-
platelet, antithrombotic, and vasodilatory effects. It is approved for treat-
ment of claudication in the United States and for secondary prevention of
cerebral infarction in Asia. The ability of antiplatelet agents to serve as
effective primary prevention in patients with diabetes is controversial. This
study suggests that perhaps the wrong antiplatelet agent is being evaluated in
diabetic patients. Progression of intima-media thickness serves only as a
surrogate marker for progression of atherosclerosis and has not been shown
to predict clinical events in patients with type 2 diabetes. The results here are
interesting and suggest a large-scale prospective study of cilostazol for
primary prevention in type 2 diabetic patients should be considered.
Vital Exhaustion as a Risk Factor for Adverse Cardiac Events (from the
Atherosclerosis Risk in Communities [ARIC] Study)
Williams JE, Mosley TH, Kop WJ, et al. Am J Cardiol 2010;105:1661-5.
Conclusion: In both men and women, vital exhaustion independently
predicts long-term risk for adverse cardiac events.
Summary: Vital exhaustion is defined as a state of excessive fatigue,
increased irritability, and demoralization. European studies have suggested a
link between vital exhaustion and coronary heart disease. The authors
attempted to use data from the Atherosclerosis Risk In Communities
(ARIC) study to provide United States data on the role of vital exhaustion
and acute coronary syndromes. The goal was to determine whether individ-
uals with low exhaustion compared with those with high vital exhaustion
were at increased risk for myocardial infarction and fatal coronary heart
disease. ARIC participants were black or white men and women aged 48 to
67 years. ARIC is a large population-based prospective study of the causeand natural history of atherosclerosis. Patients are derived fromWashington
County, Maryland; suburban Minneapolis; Forsyth County, North Caro-
lina; and Jackson, Mississippi. Patients were initially enrolled between 1987
and 1989 and have returned at approximately 3-year intervals for three
follow-up clinical examinations. Hospitalizations and death during
follow-up are identified through annual telephone interviews and hospital
surveillance.
In this study, 12,895 participants in ARIC were monitored for occur-
rence of cardiac morbidity and mortality from 1990 to 2002 (maximum
follow-up, 13.0 years). Assessment of vital exhaustion was with the 21-item
Maastricht Questionnaire. Scores were divided in quartiles for statistical
analysis. Those scoring in the fourth quartile were considered to have high
vital exhaustion. High vital exhaustion predicted adverse cardiac events in
age-, gender-, and race-adjusted analyses (1.69, 95% confidence interval
[CI], 1.40-2.05). High vital exhaustion also predicted adverse cardiac events
when adjusted for educational level, body mass index, plasma low-density
lipoprotein and high-density lipoprotein cholesterol levels, systolic and
diastolic blood pressure, diabetes mellitus, smoking, and past years of
smoking (1.46, 95% CI, 1.20-1.79). Risks for adverse cardiac events in-
creased from the first to the fourth quartile of vital exhaustion, and proba-
bilities of adverse cardiac events were higher over time in patients with high
vital exhaustion compared with those with low exhaustion levels (P .002).
Vitally exhausted participants in this study, compared with nonexhausted
peers, were more likely to be women, black, and have less formal education.
Comment:Vital exhaustion is closely linked to depression, and the two
conditions share common characteristics such as irritability and fatigue.
Fatigue does appear to be a real and measurable risk factor for cardiovascular
disease. Clearly, fatigue is associated with myocardial infarction. This is
especially so in women:70% of women in a recent study reported unusual
fatigue before myocardial infarction, with about 30% of men reporting
fatigue preceding myocardial infarction (McSweeney JC, et al, Circulation
2003;108:2619- 23). Other studies have also suggested an inverse relation-
ship between exhaustion and social and economic status (Schuitemaker GE,
et al, Psychosomatics 2004;45:414-8). TheMaastricht Questionnaire exam-
ines only the presence or absence of vital exhaustion but not the etiology. It
is possible that residual or unmeasured confounders, such as the underlying
etiology of vital exhaustion, may be additive risk factors for cardiovascular
events.
